Table 1 Patient characteristics and prognostic factors.
Characteristic | N (%) | PFS (months) [95% CI] | HR [95% CI] univariate analysis | HR [95% CI] multivariate analysis |
|---|---|---|---|---|
Female | 64 (100%) | |||
Age | ||||
> 55 | 31 (48%) | 5.7 [3.0; 14.6] | 1.00 (ref.) | 1.00 (ref.) |
≤ 55 | 33 (52%) | 3.8 [2.7; 5.6] | 1.45 [0.83; 2.53] | 1.58 [0.78; 2.41] |
Stage at initial diagnosis | ||||
Stage I–II–III | 18 (28%) | 3.7 [2.7; 6] | 1.00 (ref.) | |
Stage IV (de novo metastatic disease) | 46 (72%) | 5.1 [3.5; NR] | 0.75 [0.40; 1.41] | |
No. of metastatic sites | ||||
0 | 1 (2%) | |||
1 | 21 (33%) | 4.0 [3.0; 8.0] | 1.00 (ref.) | |
2 | 19 (30%) | 4.8 [3.0; NR] | 0.79 [0.38; 1.61] | |
≥ 3 | 23 (36%) | 3.8 [2.5; 12.4] | 0.98 [0.52; 1.87] | |
Visceral metastasis | ||||
No | 27 (42%) | 4.4 [3.0; 8.0] | 1.00 (ref.) | |
Yes | 37 (58%) | 4.1 [2.7; 6.0] | 1.02 [0.58; 1.79] | |
Bone metastasis | ||||
No | 32 (50%) | 4.4 [3.5; 7.0] | 1.00 (ref.) | |
Yes | 32 (50%) | 3.8 [2.7; 14.6] | 0.89 [0.51; 1.57] | |
Lung metastasis | ||||
No | 43 (67%) | 4.4 [3.0; 7.0] | 1.00 (ref.) | |
Yes | 21 (33%) | 4.1 [2.7; 14.6] | 0.88 [0.49; 1.59] | |
Liver metastasis | ||||
No | 46 (72%) | 4.1 [3.2; 7.0] | 1.00 (ref.) | |
Yes | 18 (28%) | 4.3 [2.5; NR] | 1.17 [0.64; 2.14] | |
Brain metastasis | ||||
No | 51 (80%) | 4.1 [3.0; 5.7] | 1.00 (ref.) | |
Yes | 13 (20%) | 5.6 [2.2; NR] | 0.86 [0.43; 1.73] | |
Initial tumor phenotype (in early stage)a | ||||
Non-TNBC | 10 (17%) | 3.0 [2.7; NR] | 1.00 (ref.) | |
HR-positive (ER and/or PR ≥ 10%) | 10 (17%) | |||
HER2-positive | 2 (3%) | |||
TNBC | 49 (83%) | 4.1 [3.0; 5.7] | 1.18 [0.55; 2.51] | |
Performance statusa | ||||
0–1 | 52 (90%) | 4.4 [3.2; 7.0] | 1.00 (ref.) | |
2–3 | 6 (10%) | 6.1 [2.5; NR] | 0.66 [0.24; 1.87] | |
Prior chemotherapy | ||||
No | 31 (48%) | 4.1 [3.2; 12.4] | 1.00 (ref.) | |
Yes | 33 (52%) | 3.7 [2.5; 8.0] | 1.18 [0.68; 2.06] | |
Prior taxane exposure | ||||
No | 33 (52%) | 5.1 [3.7; 12.4] | 1.00 (ref.) | |
Yes | 31 (48%) | 3.0 [2.5; 7.5] | 1.49 [0.86; 2.59] | |
PD-L1 status | ||||
1–10 | 42 (66%) | 3.8 [3.0; 5.7] | 1.00 (ref.) | |
≥ 10 | 22 (34%) | 4.8 [3.0; 17.3] | 0.64 [0.34; 1.19] | |
BRCA mutation status | ||||
BRCA mutation not tested | 29 (45%) | |||
BRCA mutation in tumor and/or germline | 5 (8%) | 3.8 [2.7; NR] | 1.00 (ref.) | |
No BRCA mutation found | 30 (47%) | 3.3 [2.7; 7.5] | 0.86 [0.29; 2.53] | |
Steroid use at baseline | ||||
No | 54 (84%) | 4.8 [3.5; 8.0] | 1.00 (ref.) | 1.00 (ref.) |
Yes | 10 (16%) | 2.6 [1.2; NR] | 2.86 [1.40; 5.86] | 2.73 [1.34; 5.67] |
